-DOCSTART- -X- O
Activation -X- _ O
of -X- _ O
arginine–vasopressin -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
hormonal -X- _ O
responses -X- _ O
to -X- _ O
face -X- _ O
vasodilation-related -X- _ O
hypotension. -X- _ O
Released -X- _ O
from -X- _ O
the -X- _ O
post-pituitary -X- _ O
gland -X- _ O
, -X- _ O
vasopressin -X- _ O
induces -X- _ O
vasoconstriction -X- _ O
through -X- _ O
the -X- _ O
activation -X- _ O
of -X- _ O
V1a -X- _ O
receptors -X- _ O
located -X- _ O
on -X- _ O
vascular -X- _ O
smooth -X- _ O
muscle -X- _ O
cells. -X- _ O
Due -X- _ O
to -X- _ O
its -X- _ O
non-selective -X- _ O
receptor -X- _ O
affinity -X- _ O
arginine–vasopressin -X- _ O
also -X- _ O
activates -X- _ O
V2 -X- _ O
( -X- _ O
located -X- _ O
on -X- _ O
renal -X- _ O
tubular -X- _ O
cells -X- _ O
of -X- _ O
collecting -X- _ O
ducts -X- _ O
) -X- _ O
and -X- _ O
V1b -X- _ O
( -X- _ O
located -X- _ O
in -X- _ O
the -X- _ O
anterior -X- _ O
pituitary -X- _ O
and -X- _ O
in -X- _ O
the -X- _ O
pancreas -X- _ O
) -X- _ O
receptors -X- _ O
, -X- _ O
thereby -X- _ O
potentially -X- _ O
promoting -X- _ O
undesired -X- _ O
side -X- _ O
effects -X- _ O
such -X- _ O
as -X- _ O
anti-diuresis -X- _ O
, -X- _ O
procoagulant -X- _ O
properties -X- _ O
due -X- _ O
to -X- _ O
release -X- _ O
of -X- _ O
the -X- _ O
von -X- _ O
Willebrand’s -X- _ O
factor -X- _ O
and -X- _ O
platelet -X- _ O
activation. -X- _ O
Finally -X- _ O
, -X- _ O
it -X- _ O
also -X- _ O
cross-activates -X- _ O
oxytocin -X- _ O
receptors. -X- _ O
During -X- _ O
septic -X- _ O
shock -X- _ O
, -X- _ O
vasopressin -X- _ O
plasma -X- _ O
levels -X- _ O
were -X- _ O
reported -X- _ O
to -X- _ O
be -X- _ O
lower -X- _ O
than -X- _ O
expected -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
hypersensitivity -X- _ O
to -X- _ O
its -X- _ O
vasopressor -X- _ O
effect -X- _ O
is -X- _ O
reported -X- _ O
in -X- _ O
such -X- _ O
situation. -X- _ O
Terlipressin -X- _ O
and -X- _ O
selepressin -X- _ O
are -X- _ O
synthetic -X- _ O
vasopressin -X- _ O
analogues -X- _ O
with -X- _ O
a -X- _ O
higher -X- _ O
affinity -X- _ O
for -X- _ O
the -X- _ O
V1 -X- _ O
receptor -X- _ O
, -X- _ O
and -X- _ O
, -X- _ O
hence -X- _ O
, -X- _ O
potentially -X- _ O
less -X- _ O
side -X- _ O
effects. -X- _ O
In -X- _ O
this -X- _ O
narrative -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
present -X- _ O
the -X- _ O
current -X- _ O
knowledge -X- _ O
of -X- _ O
the -X- _ O
rationale -X- _ O
, -X- _ O
benefits -X- _ O
and -X- _ O
risks -X- _ O
of -X- _ O
vasopressin -X- _ O
use -X- _ O
in -X- _ O
the -X- _ O
setting -X- _ O
of -X- _ O
septic -X- _ O
shock -X- _ O
and -X- _ O
vasoplegic -X- _ O
shock -X- _ O
following -X- _ O
cardiac -X- _ O
surgery. -X- _ O
Clearly -X- _ O
, -X- _ O
vasopressin -X- _ B-Intervention
administration -X- _ I-Intervention
allows -X- _ B-Outcome
reducing -X- _ I-Outcome
norepinephrine -X- _ I-Outcome
requirements -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
so -X- _ I-Outcome
far -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
improvement -X- _ I-Outcome
of -X- _ I-Outcome
survival -X- _ I-Outcome
was -X- _ I-Outcome
reported -X- _ I-Outcome
and -X- _ I-Outcome
side -X- _ I-Outcome
effects -X- _ I-Outcome
are -X- _ I-Outcome
frequent -X- _ I-Outcome
, -X- _ I-Outcome
particularly -X- _ I-Outcome
ischaemic -X- _ I-Outcome
events. -X- _ I-Outcome
Finally -X- _ O
, -X- _ O
we -X- _ O
will -X- _ O
discuss -X- _ O
the -X- _ O
current -X- _ O
indications -X- _ O
for -X- _ O
vasopressin -X- _ O
and -X- _ O
its -X- _ O
agonists -X- _ O
in -X- _ O
the -X- _ O
setting -X- _ O
of -X- _ O
septic -X- _ O
shock -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
remaining -X- _ O
unresolved -X- _ O
questions -X- _ O
. -X- _ O

